Fedora Goes to School: Experiences Creating a Curriculum Customization Service for K-12 Teachers

4th International Conference on Open RepositoriesThis presentation was part of the session : Fedora User Group PresentationsDate: 2009-05-20 01:30 PM – 03:00 PMEducational digital libraries provide a rich array of learning resources uniquely suited to support teachers to customize instruction. The problem we address is how to customize instruction to meet the learning needs of increasingly diverse student populations while ensuring that district learning goals and national and state standards are being met. This tension between supporting customization while supporting standards is further complicated by the challenges of scale: large urban school districts need technology infrastructure to support teachers district-wide to tailor curriculum, while still ensuring fidelity to learning goals. In partnership with Denver Public Schools (DPS), we are using open source digital library infrastructure available through the NSF-funded National Science Digital Library program to create a scalable Curriculum Customization Service. We are building on top of the Fedora-based NCore EduPak, which consists of the NSDL Collection System, the Digital Discovery System, and the NSDL Data Repository. DPS teachers will use this Service to (1) customize curriculum with digital library resources, formative assessments, and district-developed materials to aid student learning, (2) share their customizations as part of an online learning community and professional development program, and (3) discover, remix, and reuse other teachers' contributions. In this presentation, we will describe the Curriculum Customization Service and lessons learned from building an e-learning application supporting instructional planning and collaboration on top of Fedora. The Service uses learning goals as the central organizing concept of the interface. Organized around these are several curricular components including digital versions of the student textbook, digitized components of the associated teachers' guide (formative assessments, teaching tips, instructional resources, and background knowledge readings), and digital library resources. Digital library resources are further broken down by Top Picks (recommended), Images/Visuals, Animations, Additional Activities, and Working with Data. We will also present results from a 10 week pilot study with DPS middle and high school teachers (completed in Fall 2008) and plans for a large-scale, district-wide field study commencing in Fall 2009. In the pilot study, we used interviews, reflective essays, usage logs, and pop-up and email surveys to develop a detailed picture of how teachers were using the Service, and to examine how their usage of the Service changed over the course of the 10 week study. Results suggest the Service offers a powerful model for: (1) embedding digital library resources into mainstream teaching and learning practices and (2) enabling teachers to customize instruction to improve learner engagement and learning outcomes.NS

NSDL EduPak: An Open Source Education Repository Solution

4th International Conference on Open RepositoriesThis presentation was part of the session : Conference PostersEducational organizations and institutions focused on establishing specialized digital collections, conducting educational research, or providing students, teachers and instructors with discipline-oriented pedagogical products and tools require basic technology to begin building educational digital repositories. To help meet these needs, the National Science Digital Library (NSDL) has announced the release of NSDL EduPak. Specifically designed for education, NSDL EduPak packages technology for digital storage, access, and workflow into a convenient bundle. This poster reviews three core EduPak components with examples of how they are used by education communities.National Science Foundatio

Rolofylline, an adenosine A1−receptor antagonist, in acute heart failure

Background: Worsening renal function, which is associated with adverse outcomes, often develops in patients with acute heart failure. Experimental and clinical studies suggest that counterregulatory responses mediated by adenosine may be involved. We tested the hypothesis that the use of rolofylline, an adenosine A1−receptor antagonist, would improve dyspnea, reduce the risk of worsening renal function, and lead to a more favorable clinical course in patients with acute heart failure. Methods: We conducted a multicenter, double-blind, placebo-controlled trial involving patients hospitalized for acute heart failure with impaired renal function. Within 24 hours after presentation, 2033 patients were randomly assigned, in a 2:1 ratio, to receive daily intravenous rolofylline (30 mg) or placebo for up to 3 days. The primary end point was treatment success, treatment failure, or no change in the patient’s clinical condition; this end point was defined according to survival, heart-failure status, and changes in renal function. Secondary end points were the post-treatment development of persistent renal impairment and the 60-day rate of death or readmission for cardiovascular or renal causes. Results: Rolofylline, as compared with placebo, did not provide a benefit with respect to the primary end point (odds ratio, 0.92; 95% confidence interval, 0.78 to 1.09; P=0.35). Persistent renal impairment developed in 15.0% of patients in the rolofylline group and in 13.7% of patients in the placebo group (P=0.44). By 60 days, death or readmission for cardiovascular or renal causes had occurred in similar proportions of patients assigned to rolofylline and placebo (30.7% and 31.9%, respectively; P=0.86). Adverse-event rates were similar overall; however, only patients in the rolofylline group had seizures, a known potential adverse effect of A1-receptor antagonists. Conclusions: Rolofylline did not have a favorable effect with respect to the primary clinical composite end point, nor did it improve renal function or 60-day outcomes. It does not show promise in the treatment of acute heart failure with renal dysfunction. (Funded by NovaCardia, a subsidiary of Merck; ClinicalTrials.gov numbers, NCT00328692 and NCT00354458.

Directly imaging damped Lyman-alpha galaxies at z>2. I: Methodology and First Results

We present the methodology for, and the first results from, a new imaging program aimed at identifying and characterizing the host galaxies of damped Lyman-alpha absorbers (DLAs) at z>2. We target quasar sightlines with multiple optically-thick HI absorbers and use the higher-redshift system as a "blocking filter" (via its Lyman-limit absorption) to eliminate all far-ultraviolet (FUV) emission from the quasar. This allows us to directly image the rest-frame FUV continuum emission of the lower-redshift DLA, without any quasar contamination and with no bias towards large impact parameters. We introduce a formalism based on galaxy number counts and Bayesian statistics with which we quantify the probability that a candidate is the DLA host galaxy. This method will allow the identification of a bona fide sample of DLAs that are too faint to be spectroscopically confirmed. The same formalism can be adopted to the study of other quasar absorption line systems (e.g. MgII absorbers). We have applied this imaging technique to two QSO sightlines. For the z~2.69 DLA towards J073149+285449, a galaxy with impact parameter b=1.54"=11.89 kpc and implied star formation rate (SFR) of ~5 M/yr is identified as the most reliable candidate. In the case of the z~2.92 DLA towards J211444-005533, no likely host is found down to a 3-sigma SFR limit of 1.4 M/yr. Studying the HI column density as a function of the impact parameter, including 6 DLAs with known hosts from the literature, we find evidence that the observed HI distribution is more extended than what is generally predicted from numerical simulation.Comment: 22 pages, 13 figures. Accepted for publication in MNRAS. Typos correcte

Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study

Although dyspnoea is the most common cause of admission for acute heart failure (AHF), more needs to be known about its clinical course and prognostic significance. The Pre-RELAX-AHF study randomized 232 subjects with AHF to placebo or four doses of relaxin and evaluated early (6-24 h Likert scale) and persistent [change in visual analogue scale area under the curve (VAS AUC) through Day 5] dyspnoea relief. Worsening heart failure (WHF) was defined as worsening AHF signs and symptoms requiring additional therapy. Patients were followed until Day 180. Early dyspnoea relief was observed in only 25% of all patients, and VAS AUC at 5 days was 45% over baseline values in all patients (32% placebo; 50% all relaxin-treated patients). Worsening heart failure to Day 5 was observed in 16% of all patients (21% placebo; 14% relaxin). Lack of persistent dyspnoea relief and WHF were associated with a longer length of initial hospital stay and worse 60-day outcomes. Dyspnoea relief in patients admitted with AHF is often incomplete, and many may show WHF after the initial stabilization. Both lack of persistent dyspnoea relief and in-hospital WHF predict a longer length of stay and worse outcome

Global development and diffusion of outcome evaluation research for interpersonal and self-directed violence prevention from 2007 to 2013: A systematic review

© 2014 The Authors. Published by Elsevier Ltd. Through a global review, we identified gaps in the geographical distribution of violence prevention evidence outcome evaluation studies and the types of violence addressed. Systematic literature searches identified 355 articles published between 2007 and 2013 that evaluated programs to prevent interpersonal or self-directed violence; focused on universal or selected populations; and reported outcomes measuring violence or closely related risk factors. The number of studies identified increased annually from 2008 (n = 37), reaching 64 in 2013. Over half (n = 203) of all studies focused on youth violence yet only one on elder maltreatment. Study characteristics varied by year and violence type. Only 9.3% of all studies had been conducted in LMICs. These studies were less likely than those in high income countries (HICs) to have tested established interventions yet more likely to involve international collaboration. Evaluation studies successfully established in LMIC had often capitalized on other major regional priorities (e.g. HIV). Relationships between violence and social determinants, communicable and non-communicable diseases, and even economic prosperity should be explored as mechanisms to increase the global reach of violence prevention research. Results should inform future research strategies and provide a baseline for measuring progress in developing the violence prevention evidence-base, especially in LMICs

Vasodilators in the treatment of acute heart failure: what we know, what we don’t

Although we have recently witnessed substantial progress in management and outcome of patients with chronic heart failure, acute heart failure (AHF) management and outcome have not changed over almost a generation. Vasodilators are one of the cornerstones of AHF management; however, to a large extent, none of those currently used has been examined by large, placebo-controlled, non-hemodynamic monitored, prospective randomized studies powered to assess the effects on outcomes, in addition to symptoms. In this article, we will discuss the role of vasodilators in AHF trying to point out which are the potentially best indications to their administration and which are the pitfalls which may be associated with their use. Unfortunately, most of this discussion is only partially evidence based due to lack of appropriate clinical trials. In general, we believe that vasodilators should be administered early to AHF patients with normal or high blood pressure (BP) at presentation. They should not be administered to patients with low BP since they may cause hypotension and hypoperfusion of vital organs, leading to renal and/or myocardial damage which may further worsen patients’ outcome. It is not clear whether vasodilators have a role in either patients with borderline BP at presentation (i.e., low-normal) or beyond the first 1–2 days from presentation. Given the limitations of the currently available clinical trial data, we cannot recommend any specific agent as first line therapy, although nitrates in different formulations are still the most widely used in clinical practice

Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)

Introduction The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness and fatigue whether hospitalised or not. Early data suggest potentially severe long-term consequence of COVID-19 is development of long COVID-19-related interstitial lung disease (LC-ILD). Methods and analysis The UK Interstitial Lung Disease Consortium (UKILD) will undertake longitudinal observational studies of patients with suspected ILD following COVID-19. The primary objective is to determine ILD prevalence at 12 months following infection and whether clinically severe infection correlates with severity of ILD. Secondary objectives will determine the clinical, genetic, epigenetic and biochemical factors that determine the trajectory of recovery or progression of ILD. Data will be obtained through linkage to the Post-Hospitalisation COVID platform study and community studies. Additional substudies will conduct deep phenotyping. The Xenon MRI investigation of Alveolar dysfunction Substudy will conduct longitudinal xenon alveolar gas transfer and proton perfusion MRI. The POST COVID-19 interstitial lung DiseasE substudy will conduct clinically indicated bronchoalveolar lavage with matched whole blood sampling. Assessments include exploratory single cell RNA and lung microbiomics analysis, gene expression and epigenetic assessment. Ethics and dissemination All contributing studies have been granted appropriate ethical approvals. Results from this study will be disseminated through peer-reviewed journals. Conclusion This study will ensure the extent and consequences of LC-ILD are established and enable strategies to mitigate progression of LC-ILD